News | March 23, 2026
Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The company announced positive topline data from the Phase II ZUPREME-1 trial
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
Subscribe To Our Newsletter & Stay Updated
